• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

American Cancer Society 2014 Cancer Facts and Figures

By Nascent Biotech
 Posted June 3, 2014
 In Science News
American Cancer Society 2014 Cancer Facts and Figures2014-06-032014-06-03http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttps://www.nascentbiotech.com/wp-content/uploads/2014/06/Screen-Shot-2014-06-03-at-8.23.44-AM.png200px200px
0

Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society.

In addition, please review this document, entitled “Cancer Statistics, 2011; The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths” in PDF format.

Recent Posts
  • Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma
    Nascent Biotech Inc (OTCMKTS: NBIO) Steady Rise Northbound as Phase 1 Clinical Trials Progress for Pritumumab (PTB) Targeting Glioblastoma
  • Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
    Nascent Biotech Completes Third Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
  • Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
    Nascent Biotech’s CEO Sean Carrick Featured in In-Depth Interview with Proactive Investors
  • Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
    Nascent Biotech and BioTools Partner in the Fight Against Cancer Using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.
Nascent Team Members Contribute to “Human Monoclonal Antibodies” (Humana Press)Science News